{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:02Z","timestamp":1791389522737,"version":"4.3.3"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Currently lack of consensus regarding the medical treatment of men with Oligoasthenoteratozoospermia (OATS). Letrozole is an aromatase inhibitor and may improve semen quality by stimulating hormone synthesis and spermatogenesis. There is lack of evidence on the efficacy and safety of letrozole as therapy for male infertility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To study the efficacy of letrozole in improving semen parameters, hormonal profile of participants with moderate-to-severe OATS and its side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>Randomised double-blinded placebo-controlled trials conducted in a tertiary care centre conducted between August 2021 and July 2023. Men with abnormal semen analysis reports between the age group of 21 and 45 years with moderate-to-severe OATS visiting the male infertility clinic were enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Fifty-four men were randomised into two groups. Twenty-eight men in A (intervention group) received letrozole, and 24 men in Group B (control group) received a placebo after written informed consent. After 3 months, semen analysis and hormonal parameters were studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>\n                      Data analysis was performed using SPSS version 19 (IBM). Associations between categorical variables in two groups were analysed using the Chi-square test or Fisher\u2019s exact test. Continuous variables were compared using the Mann\u2013Whitney test, and independent Students\u2019\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test and pre- and post-treatment comparisons of continuous variables were assessed using a paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test or Wilcoxon signed-rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Total sperm count increased by 4.4 (2.8, 8.8) million per ejaculate, sperm concentration by 3.2 (1, 4.4) million\/mL and progressive motility by 5.8 \u00b1 7.3% compared to the placebo group, which was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). The use of letrozole had minor side effects like headache and nausea. Letrozole use in men with OATS showed a significant improvement in follicle-stimulating hormone by 6.8 \u00b1 5.5 mIU\/mL, luteinising hormone by 6.3 \u00b1 3.3 IU\/L, testosterone by 193.3 \u00b1 130 ng\/dL, with\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value of 0.001 and significant fall in oestradiol by 17.6 \u00b1 7.9 pg\/mL overall improving T\/E ratio by 18.4 \u00b1 8.8.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Letrozole use may result in improving semen parameters in men with moderate-to-severe OATS. However, these findings need to be validated in larger trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jhrs.jhrs_160_24","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:54:52Z","timestamp":1743360892000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Letrozole in Improving Semen Parameters of Subfertile Men with Moderate-to-Severe Oligoasthenoteratozoospermia: A Placebo-controlled Randomised Trial"],"prefix":"10.4103","volume":"18","author":[{"given":"Pallavi","family":"Ullur","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, AIIMS, Bibinagar, Telangana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Kubera","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soliappappan","family":"Manikandan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, AIIMS, Bibinagar, Telangana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusuya","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The international glossary on infertility and fertility care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0974-1208.170370","article-title":"Trends of male factor infertility, an important cause of infertility: A review of literature","volume":"8","author":"Kumar","year":"2015","journal-title":"J Hum Reprod Sci"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.fertnstert.2018.08.015","article-title":"Male infertility as a window to health","volume":"110","author":"Choy","year":"2018","journal-title":"Fertil Steril"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.fertnstert.2014.12.122","article-title":"On-label and off-label drugs used in the treatment of male infertility","volume":"103","author":"Chehab","year":"2015","journal-title":"Fertil Steril"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/en.2009-1477","article-title":"Estradiol induction of spermatogenesis is mediated via an estrogen receptor-{alpha} mechanism involving neuroendocrine activation of follicle-stimulating hormone secretion","volume":"151","author":"Allan","year":"2010","journal-title":"Endocrinology"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/andr.13388","article-title":"Clomiphene citrate for male infertility: A systematic review and meta-analysis","volume":"11","author":"Huijben","year":"2023","journal-title":"Andrology"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/19396368.2014.994789","article-title":"Hormonal therapy (hCG and rhFSH) for infertile men with adult-onset idiopathic hypogonadotropic hypogonadism","volume":"61","author":"Kobori","year":"2015","journal-title":"Syst Biol Reprod Med"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.fertnstert.2012.10.023","article-title":"Aromatase inhibitors for male infertility","volume":"98","author":"Schlegel","year":"2012","journal-title":"Fertil Steril"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"121074.","DOI":"10.1016\/j.lfs.2022.121074","article-title":"Letrozole: Pharmacology, toxicity and potential therapeutic effects","volume":"310","author":"Mukherjee","year":"2022","journal-title":"Life Sci"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/aja.aja_101_19","article-title":"A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility","volume":"22","author":"Del Giudice","year":"2020","journal-title":"Asian J Androl"},{"key":"R11-20260423","first-page":"1368.","article-title":"The sixth edition of the WHO manual for human semen analysis: A critical review and SWOT analysis","volume":"11","author":"Boitrelle","year":"2021","journal-title":"Life (Basel)"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"e4194","DOI":"10.1210\/clinem\/dgaa390","article-title":"Nonsurgical management of oligozoospermia","volume":"105","author":"Choy","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.2047-2927.2013.00107.x","article-title":"Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: A meta-analysis","volume":"1","author":"Chua","year":"2013","journal-title":"Andrology"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/andr.12197","article-title":"Tamoxifen in men: A review of adverse events","volume":"4","author":"Wibowo","year":"2016","journal-title":"Andrology"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/andr.12333","article-title":"Short-term FSH treatment and sperm maturation: A prospective study in idiopathic infertile men","volume":"5","author":"Casamonti","year":"2017","journal-title":"Andrology"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0022-5347(05)66540-8","article-title":"Evidence of a treatable endocrinopathy in infertile men","volume":"165","author":"Pavlovich","year":"2001","journal-title":"J Urol"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"829.e1","DOI":"10.1016\/j.fertnstert.2009.05.014","article-title":"Use of the aromatase inhibitor letrozole to treat male infertility","volume":"92","author":"Patry","year":"2009","journal-title":"Fertil Steril"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.fertnstert.2010.09.021","article-title":"The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men","volume":"95","author":"Saylam","year":"2011","journal-title":"Fertil Steril"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/aja.2013.99","article-title":"Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: A pilot study","volume":"15","author":"Cavallini","year":"2013","journal-title":"Asian J Androl"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rbmo.2018.09.016","article-title":"Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility?","volume":"38","author":"Shuling","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.fertnstert.2012.04.005","article-title":"Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios","volume":"98","author":"Gregoriou","year":"2012","journal-title":"Fertil Steril"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12958-020-00591-2","article-title":"Effect of letrozole on sperm parameters, chromatin status and ROS level in idiopathic Oligo\/Astheno\/Teratozoospermia","volume":"18","author":"Kooshesh","year":"2020","journal-title":"Reprod Biol Endocrinol"}],"container-title":["Journal of Human Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_160_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:59Z","timestamp":1786647659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_160_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jhrs.jhrs_160_24","relation":{},"ISSN":["0974-1208","1998-4766"],"issn-type":[{"value":"0974-1208","type":"print"},{"value":"1998-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}